Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Page Options
E-Mail This Search
Clinical Trial Questions?
Get Help:
1-800-4-CANCER
or
LiveHelp online chat
Quick Links
Help Using the NCI Clinical Trials Search Form
Educational Materials About Clinical Trials
About NCI's Cancer Clinical Trials Registry
Dictionary of Cancer Terms
NCI Drug Dictionary
View Content for:
Patients
Health Professionals
Display:
Title
Description with:
Locations
Eligibility
Full Trial Description
Custom
Results 1-7 of 7 for your search:
Drug:
poly ICLC
Find trials that include:
Any drugs shown
Trial Status:
Active
Hide Search Criteria
Show Search Criteria
Help with Results
Select All on Page
Sort by:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Show
10
25
50
100
200
Results per Page
1.
Phase I/II Study of 3-Dimensional Conformal Radiotherapy, Intra- or Peri-Tumoral Injection of Poly ICLC With Trans-Hepatic Arterial Embolization Followed by Autologous Tumor Cell Vaccine Poly ICLC in Patients With Unresectable, Recurrent, or Metastatic Primary Hepatocellular or Pancreatic Cancer
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
UMDNJ-0120070076
, 0120070076, NCT00553683
2.
Vaccination-Dendritic Cells With Peptides for Recurrent Malignant Gliomas
Phase:
Phase II, Phase I
Type:
Treatment
Status:
Active
Age:
Over 18
Sponsor:
Other
Protocol IDs:
05-115
, RO1 NS055140, NCT00766753
3.
Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma
Phase:
Phase I
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
NVCI-0838
, NCT00880867
4.
PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
NCI, Other
Protocol IDs:
MCC-15262
, USFIRB #106346, NCT00694551
5.
Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas
Phase:
No phase specified
Type:
Treatment
Status:
Active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
07-057
, R21CA133859-01A1, NCT00795457
6.
Pilot Study of HLA-A2-Restricted Synthetic Glioma Antigen Peptide Vaccine and Poly ICLC Vaccine in Young Patients With Newly Diagnosed Malignant or Intrinsic Brain Stem Glioma, Incompletely Resected Non-Brainstem High-Grade Glioma, or Recurrent Unresectable Low-Grade Glioma
Phase:
No phase specified
Type:
Biomarker/Laboratory analysis, Treatment
Status:
Active
Age:
3 to 20
Sponsor:
Other
Protocol IDs:
CHP-PRO08030085
, PRO08030085, NCT00862199
7.
HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas
Phase:
No phase specified
Type:
Treatment
Status:
Approved-not yet active
Age:
18 and over
Sponsor:
Other
Protocol IDs:
08-135
, 2P01NS040923-06A1, NCT00874861
Select All on Page
Help with Results
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute